News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Supernus Pharmaceuticals (SUPN) Receives $2 Million Milestone For United Therapeutics Corporation (UTHR)' Launch Of Orenitram™



5/21/2014 9:32:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., May 20, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that United Therapeutics Corporation (Nasdaq:UTHR) has paid Supernus a $2 million milestone payment under United Therapeutics' license agreement with Supernus. This payment was due upon the launch of Orenitramâ„¢ (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension, in the United States. Orenitramâ„¢ utilizes a Supernus patented technology platform. In addition to the launch milestone, Supernus will receive royalties on net sales of Orenitramâ„¢, and may become entitled to additional milestone payments.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES